9 assets in Low Grade Glioma

Therapeutic assets addressing Low Grade Glioma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Irinotecan Low Grade Glioma	Beijing Sanbo Brain Hospital	P2	BB (64)
Binimetinib Low Grade Glioma	National Cancer Center, Japan	P2	CCC (53)
Nivolumab Low Grade Glioma	National Cancer Institute (NCI)	P2	CCC (53)
Plixorafenib Low Grade Glioma	Fore Biotherapeutics	P2	CCC (50)
Avutometinib Low Grade Glioma	Memorial Sloan Kettering Cancer Center	P1	CC (43)
Claturafenib Low Grade Glioma	Pfizer	P1	CC (43)
Pamiparib Low Grade Glioma	University of California, San Francisco	P1	CC (43)
pf-07799544 Low Grade Glioma	Pfizer	P1	CC (43)
Tovorafenib Low Grade Glioma	Day One Biopharmaceuticals, Inc.	P2	CC (43)